Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1879.

https://doi.org/10.1182/blood-2019-124339

Published: 2019

Journal Articles

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja Zweegman, MD PhD, Marie José Kersten, MD, Edo Vellenga, MD, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Monique C Minnema, Sarah Lonergan, Antonio Palumbo, MD, Henk M Lokhorst, Annemiek Broyl, MD PhD, Karim Saad Iskander, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3141.

https://doi.org/10.1182/blood.V130.Suppl_1.3141.3141

Published: 2017

Journal Articles

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Blood (2017) 130 (Supplement 1): 2606.

https://doi.org/10.1182/blood.V130.Suppl_1.2606.2606

Published: 2017

Journal Articles

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Geert Huls, MD PhD, Dana Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, MD PhD, Arjen van de Loosdrecht, Bart J. Biemond, MD PhD, Harm Sinnege, MDPhD, Beata Hodossy, Carlos Graux, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Dimitri Breems, MD PhD, Saskia Klein, MD, Jurgen Kuball, MD, Gert J. Ossenkoppele, MD PhD, Bob Lowenberg, MD PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 463.

https://doi.org/10.1182/blood.V130.Suppl_1.463.463

Published: 2017

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

Annemiek Broijl, MDPhD, Marie José Kersten, MD PhD, Wendim Ghidey Alemayehu, PhD, Mark-David Levin, MDPhD, Okke de Weerdt, MD, Edo Vellenga, MDPhD, Ellen Meijer, MDPhD, Shulamiet Wittebol, MDPhD, Rosita Ghiraw-Visser, Marian Stevens-Kroef, PhD, Berna Beverloo, PhD, Gerard M.J. Bos, MDPhD, Pierre W. Wijermans, MDPhD, Henk Lokhorst, MDPhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 4735.

https://doi.org/10.1182/blood.V124.21.4735.4735

Published: 2014

Journal Articles

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Pieter Sonneveld, MD, Ph.D, Emilie Asselberg-Hacker, Sonja Zweegman, MD PhD, Bronno van der Holt, Marie Jose Kersten, MD, PhD, Edo Vellenga, Marinus van Marwijk Kooy, MD, PhD, Okke de Weerdt, MD, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk Lokhorst

Blood (2013) 122 (21): 688.

https://doi.org/10.1182/blood.V122.21.688.688

Published: 2013

Journal Articles

Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

Pieter Sonneveld, MD, PhD, Emilie Hacker, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD, PhD, Edo Vellenga, PhD, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, MD, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD

Blood (2011) 118 (21): 633.

https://doi.org/10.1182/blood.V118.21.633.633

Published: 2011

Journal Articles

An Observational Post Authorization Study on the Use of Bortezomib in Multiple Myeloma Patients in the Netherlands: Results of An Interim Analysis

Henk Lokhorst, Cornelis van Der Heul, M.D., Henk Roerdink, Okke de Weerdt, MD

Blood (2008) 112 (11): 5200.

https://doi.org/10.1182/blood.V112.11.5200.5200

Published: 2008

Journal Articles

A Phase I Trial of Dose Escalating Simvastatin Combined with Chemotherapy in End-Stage Myeloma and Lymphoma.

Henk M. Lokhorst, MD, PhD, Niels van de Donk, MD, PhD, Ellen van de Spek, MD, Okke de Weerdt, MD, Rene van de Griend, MD, PhD, Shulamiet Wittebol, MD, Leo F. Verdonck, MD, PhD, Andries C. Bloem, MD, PhD

Blood (2004) 104 (11): 3458.

https://doi.org/10.1182/blood.V104.11.3458.3458

Published: 2004

NARROW

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

An Observational Post Authorization Study on the Use of Bortezomib in Multiple Myeloma Patients in the Netherlands: Results of An Interim Analysis

A Phase I Trial of Dose Escalating Simvastatin Combined with Chemotherapy in End-Stage Myeloma and Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only